Vnitr Lek 2017, 63(12):930-931 | DOI: 10.36290/vnl.2017.168

Postavení warfarinu v dnešní době: budeme jej ještě potřebovat? - editorial

Jan Kvasnička
Centrální hematologické laboratoře a Trombotické centrum Ústavu lékařské biochemie a laboratorní diagnostiky 1. LF UK a VFN v Praze

Received: September 26, 2017; Published: December 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kvasnička J. Postavení warfarinu v dnešní době: budeme jej ještě potřebovat? - editorial. Vnitr Lek. 2017;63(12):930-931. doi: 10.36290/vnl.2017.168.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. IMS Dataview - software společnosti Quintiles IMS. Dostupné z WWW: <http://www.quintiles.com>.
    2. Guyatt GH, Akl EA, Crowther M et al. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 Suppl): 7S-47S. Dostupné z DOI: <http://dx.doi.org/10.1378/chest.1412S3>. Erratum in Chest 2012; 141(4): 1129. Dosage error in article text. Chest 2012; 142(6): 1698. Dosage error in article text. Go to original source... Go to PubMed...
    3. Čihák R, Heinc P, Haman L et al. Fibrilace síní. Doporučený diagnostický a léčebný postup České kardiologické společnosti vypracovaný Pracovní skupinou arytmie a trvalé kardiostimulace. Cor Vasa 2011; 53(Suppl 1): 27-52. Go to original source...
    4. Kvasnička J, Hájková J, Bobčíková P et al. Prevalence polymorfismů CYP2C9 a VKORC1 v České republice a zamyšlení nad výhledy antikoagulační léčby warfarinem. Cor Vasa 2011; 53(10): 522-526. Go to original source...
    5. Baumgartner H, Falk V, Bax JJ et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2017; 38(36): 2739-2791. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehx391>. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.